GRI Bio (NASDAQ:GRI) Price Target Raised to $35.00 at Ascendiant Capital Markets

GRI Bio (NASDAQ:GRI) had its price target boosted by Ascendiant Capital Markets from $34.00 to $35.00 in a research note released on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating on shares of GRI Bio in a research report on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.50.

GRI Bio Stock Performance

GRI Bio stock opened at $2.00 on Monday. The stock has a fifty day moving average of $1.62 and a two-hundred day moving average of $2.06. The company has a market capitalization of $5.04 million, a price-to-earnings ratio of -0.17 and a beta of -1.59. GRI Bio has a fifty-two week low of $1.10 and a fifty-two week high of $30.43.

GRI Bio (NASDAQ:GRI) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.31) earnings per share for the quarter, hitting the consensus estimate of ($1.31). On average, analysts forecast that GRI Bio will post -3.04 EPS for the current fiscal year.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.